Akathisia is a sense of inner restlessness — a near-physical compulsion to move — usually paired with visible motor signs like pacing, shifting from foot to foot, leg crossing, or constant repositioning in a chair. The word comes from the Greek for "inability to sit." It is one of the most distressing side effects of antipsychotic medication, and one of the most frequently mistaken for something else.
Akathisia is a movement-based side effect of dopamine-blocking medications characterised by an aversive, often unbearable inner restlessness, treatable with dose reduction, propranolol, mirtazapine, benzodiazepines, or a switch in antipsychotic.
What akathisia actually feels like
Patients describe it variably as: "wanting to crawl out of my skin," "an electric current running through me," "fidgeting that comes from inside," "needing to walk or I will scream." The aversive quality is the hallmark — this is not the pleasant restlessness of being excited. It is a near-painful compulsion. Many patients with akathisia have been mislabelled as anxious, agitated, or psychotically activated. Several reviews have linked unrecognised akathisia to medication discontinuation and to elevated suicide risk in observational data, which is one reason the symptom is taken so seriously by clinicians who recognise it.
How akathisia is diagnosed
The Barnes Akathisia Rating Scale (BARS) is the most widely used structured assessment. It scores objective movement, subjective awareness of restlessness, subjective distress about restlessness, and a global rating. A BARS score of 2 or more on the global rating typically prompts intervention. Diagnosis is otherwise clinical: a history of recent antipsychotic start or dose increase, the characteristic combination of restlessness and movement, and the absence of better explanations.
Why dopamine blockers cause akathisia
The mechanism is incompletely understood. Leading hypotheses involve disruption of mesocortical dopamine signalling and downstream effects on noradrenergic and serotonergic systems. Unlike other EPS, akathisia does not always respond to anticholinergics — which suggests it is not a pure dopamine–acetylcholine imbalance problem. The fact that propranolol (a beta-blocker) and mirtazapine (a 5-HT2A antagonist) are the best-evidence treatments points to broader monoaminergic involvement.
Risk factors
- Higher antipsychotic doses
- Rapid titration
- High-potency D2 blockers (haloperidol, fluphenazine)
- Partial agonists (aripiprazole, cariprazine, brexpiprazole) at certain doses
- Risperidone and paliperidone, particularly above mid-range doses
- Lurasidone
- Iron deficiency (some evidence)
- Prior history of akathisia
Clozapine and quetiapine have the lowest rates. Olanzapine has moderate-to-low rates. Lumateperone showed low rates in pivotal trials.
Treatment
The general sequence used in clinical practice, summarised by reviews such as those in NICE CG178 and the American Psychiatric Association schizophrenia guideline:
1. Lower the dose
The first move when feasible. Akathisia is typically dose-related. Even a modest dose reduction can resolve it. The trade-off is the risk of psychiatric symptom return, which has to be weighed.
2. Add propranolol
Beta-blockers, particularly propranolol, are the most consistent evidence-based addition. Typical regimens use 20–40 mg three times daily, titrated up as tolerated. Watch for hypotension, bradycardia, and bronchospasm in patients with asthma or COPD.
3. Add mirtazapine
Mirtazapine 15 mg at bedtime has consistently shown akathisia reduction in randomised trials and is increasingly used as a first-line addition, especially when sleep or appetite are also issues. Sedation is the main downside.
4. Short-term benzodiazepine
Lorazepam or clonazepam can provide rapid relief while other treatments are titrated. Long-term benzodiazepine use is generally avoided because of dependence and sedation.
5. Anticholinergic (sometimes)
Benztropine and trihexyphenidyl are less consistently effective for akathisia than for dystonia or parkinsonism. They are sometimes used when the patient also has parkinsonism. Cognitive side effects in older patients limit use.
6. Switch antipsychotic
If akathisia persists despite the steps above, switching to a lower-akathisia agent (clozapine, quetiapine, olanzapine) is often the path that ends it. The decision to switch belongs with the prescribing clinician, not the patient acting alone.
Tardive akathisia: a special case
Like tardive dyskinesia, akathisia can also become "tardive" — appearing after long-term exposure and sometimes persisting after the medication is stopped. Tardive akathisia is rarer than tardive dyskinesia but harder to treat. Some clinicians use VMAT2 inhibitors (valbenazine, deutetrabenazine) off-label for it, with mixed evidence.
You feel an unbearable urge to move that is paired with thoughts of self-harm, you are pacing for hours and unable to rest, or the restlessness is escalating despite a stable dose. Untreated akathisia is a medical problem, not a personality trait.
What patients can do
- Name it. Tell your prescriber the word "akathisia" and describe what you feel inside, not just what others see.
- Track the timing — when it started, how it relates to dose changes, when it is worst.
- Ask for a Barnes scale assessment.
- Bring up specific options (propranolol, mirtazapine, dose reduction, switch).
- Push for a real plan if the response is "give it time" — give-it-time alone is not standard care.
The lived experience
Patients who have come through akathisia often describe it as the worst part of their psychiatric treatment, more than the original psychotic symptoms. The good news is that with the right combination of dose adjustment, augmentation, and (if needed) a switch, most akathisia resolves. The bad news is that this only happens when the symptom is identified. A recurring story in the schizophrenia community is months or years of misery from akathisia that ends within weeks of a competent intervention.
For more, see our EPS overview, akathisia management, and propranolol for akathisia.
This article is for educational purposes only and is not medical advice, diagnosis, or treatment. Always consult a qualified mental health professional. If you or someone you know is in crisis, call or text 988 in the US, or your local emergency number.